Pamela Munster

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U Lin
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 133:1057-65. 2012
  2. ncbi Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer
    Pamela N Munster
    University of California, San Francisco, CA, USA
    J Clin Oncol 30:533-8. 2012
  3. ncbi Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC
    Pamela Munster
    Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California 94143 1711, USA
    Clin Cancer Res 15:2488-96. 2009
  4. ncbi Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
    P N Munster
    Division of Hematology and Oncology, University of California, San Francisco, CA 94143, USA
    Br J Cancer 101:1044-50. 2009
  5. ncbi A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
    P N Munster
    Division of Hematology and Oncology, University of California, San Francisco, 1600 Divisadero, Rm A719 Box 1711, San Francisco, CA 94143, USA
    Br J Cancer 104:1828-35. 2011
  6. ncbi Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma
    Pamela N Munster
    University of California, Department of Medicine, San Francisco, CA, USA
    Expert Opin Investig Drugs 20:1565-74. 2011

Research Grants

  1. The Role of Selective HDAC Enzymes in Drug Sensitivity
    Pamela N Munster; Fiscal Year: 2010

Collaborators

  • S Thomas
  • Adil Daud
  • Charles E Cox
  • Susan E Minton
  • A Miller
  • Nancy U Lin
  • Eric P Winer
  • Laurie Frakes
  • Susan Cleator
  • Tamas Hickish
  • Sven Wind
  • Duncan Wheatley
  • David Mendelson
  • Stephen Houston
  • Richard Vinisko
  • Hilary Jones
  • Martina Uttenreuther-Fischer
  • Agustin A Garcia
  • Lisa A Carey
  • Steve Kelly

Detail Information

Publications6

  1. ncbi A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U Lin
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 133:1057-65. 2012
    ..4%) and rash (9.8%). Afatinib monotherapy was associated with promising clinical activity in extensively pretreated HER2-positive breast cancer patients who had progressed following trastuzumab treatment...
  2. ncbi Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer
    Pamela N Munster
    University of California, San Francisco, CA, USA
    J Clin Oncol 30:533-8. 2012
    ..This prospective randomized trial evaluated the use of gonadotropin-releasing hormone (GnRH) analog triptorelin to preserve ovarian function in women treated with chemotherapy for early-stage breast cancer...
  3. ncbi Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC
    Pamela Munster
    Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California 94143 1711, USA
    Clin Cancer Res 15:2488-96. 2009
    ..The aim was to study the biological and molecular effects of the histone deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies...
  4. ncbi Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
    P N Munster
    Division of Hematology and Oncology, University of California, San Francisco, CA 94143, USA
    Br J Cancer 101:1044-50. 2009
    ..Histone deacetylase inhibitors (HDACi) can sensitise cancer cells to topoisomerase inhibitors by increasing their access and binding to DNA...
  5. ncbi A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
    P N Munster
    Division of Hematology and Oncology, University of California, San Francisco, 1600 Divisadero, Rm A719 Box 1711, San Francisco, CA 94143, USA
    Br J Cancer 104:1828-35. 2011
    ..Preclinically, HDAC inhibitors can reverse tamoxifen/aromatase inhibitor resistance in hormone receptor-positive breast cancer. This concept was examined in a phase II combination trial with correlative end points...
  6. ncbi Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma
    Pamela N Munster
    University of California, Department of Medicine, San Francisco, CA, USA
    Expert Opin Investig Drugs 20:1565-74. 2011
    ..The treatment for melanoma is in rapid transition and genomic profiling is now an integral part, and hence the optimal use of karenitecin in melanoma should be re-evaluated with regard to specific mutational status...

Research Grants3

  1. The Role of Selective HDAC Enzymes in Drug Sensitivity
    Pamela N Munster; Fiscal Year: 2010
    ..In pre- and post-treatment tumor samples, we will determine which HDACs are involved in the cellular effects induced by the HDACi and which HDACs may predict response. ..